Tempest Partners with Roche for Liver Cancer Therapy Trial
Tempest Therapeutics Announces Strategic Partnership with Roche
Tempest Therapeutics, Inc. (NASDAQ: TPST), a dynamic clinical-stage biotechnology firm, has recently unveiled an exciting partnership with Roche, aimed at promoting the evaluation of amezalpat (also known as TPST-1120). This collaboration specifically targets the use of amezalpat alongside atezolizumab (Tecentriq) and bevacizumab in a crucial pivotal Phase 3 trial aimed at first-line treatment for hepatocellular carcinoma (HCC), also known as liver cancer.
Details of the Agreement
This agreement marks a significant milestone for Tempest, as Roche will provide atezolizumab on a global scale while Tempest will spearhead the management of this pivotal clinical study. Their joint efforts will stem from a previous collaboration wherein amezalpat was assessed alongside the current standard of care—atezolizumab and bevacizumab—in a randomized Phase 1b/2 study involving first-line HCC patients. Tempest maintains exclusive development and commercial rights to amezalpat, reinforcing its position in the cancer treatment landscape.
CEO Comments on the Collaboration
Stephen Brady, the president and CEO of Tempest, expressed enthusiasm regarding this partnership. He stated, "We're thrilled to announce this agreement that supports the advancement of amezalpat into a pivotal study and underscores both Tempest’s and Roche’s commitment to pioneering cancer therapies for patients. We believe that the combination therapy has significant potential to enhance treatment outcomes for those battling liver cancer." He highlighted the encouraging Phase 2 data which indicates transformative potential for improving first-line liver cancer treatment through this collaboration.
Reaffirming Clinical Benefits
In the earlier stages of the trial, Tempest reported impressive survival data showcasing a six-month increase in median overall survival for patients undergoing the combination therapy compared to those receiving the standard care regimen of atezolizumab and bevacizumab. This survival advantage was particularly notable across key subpopulations, reiterating the compound's clinical value. Moreover, findings suggested notable efficacy regardless of patients' PD-L1 status and in those with immune excluded and immune desert tumors.
Plans for Phase 3 Study
In its meeting with the FDA, Tempest secured an agreement regarding the Phase 3 study's design, which includes the amezalpat dosage and a primary endpoint focused on overall survival. Additionally, the statistical plan was discussed, which may potentially accelerate the timeline to the primary analysis of the study by eight months. The company is gearing up for the commencement of this pivotal Phase 3 trial, anticipated to begin in the first quarter of 2025.
Overview of the TPST-1120-301 Study
The upcoming Phase 3 investigation is laid out to be a global, blinded, and randomized study. It will compare the combination of amezalpat plus atezolizumab and bevacizumab against the standard of care—atezolizumab plus bevacizumab—in patients diagnosed with unresectable or metastatic HCC. With a robust go-ahead timeline from the FDA, the groundwork is set for advancing innovative treatments for liver cancer.
About Amezalpat (TPST-1120)
Amezalpat is classified as an oral, small molecule, selective PPAR? antagonist. Clinical studies indicate it operates by directly targeting tumor cells while also modulating the immune suppressive cells and influencing angiogenesis within the tumor microenvironment. The ongoing global randomized Phase 1b/2 study has shown amezalpat to significantly outperform standard treatments regarding various study endpoints, particularly overall survival rates.
About Tempest Therapeutics
Tempest Therapeutics is dedicated to developing a diverse array of small molecule therapy candidates, focusing on tumor-targeted and immune-mediated approaches. Their novel methods are under ongoing research, progressing from initial studies to advanced phases of trials. Based in Brisbane, California, Tempest Therapeutics continuously seeks to innovate and expand its impact in the field of oncology.
Frequently Asked Questions
What is the main objective of the partnership between Tempest and Roche?
The partnership aims to advance the evaluation of amezalpat in combination with other therapies for treating hepatocellular carcinoma in a pivotal Phase 3 trial.
What are the expected outcomes of the Phase 3 trial?
The Phase 3 trial aims to demonstrate the efficacy of amezalpat combined with atezolizumab and bevacizumab in improving overall survival rates for patients with liver cancer.
What does amezalpat target in cancer treatment?
Amezalpat targets tumor cells directly and modulates immune suppressive cells and angiogenesis in the tumor microenvironment.
When is the Phase 3 study expected to begin?
The study is expected to commence in the first quarter of 2025, following the recent agreement with the FDA.
Where is Tempest Therapeutics located?
Tempest Therapeutics is headquartered in Brisbane, California, focusing on innovative cancer treatment solutions.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Silynxcom Secures Significant Order for Tactical Communication Headsets
- Expanding Horizons: Harbor Capital Unveils New ETF for Investors
- Celebrate Parisian Sophistication with Chamère's Kir Royale
- Wereldhave Achieves Top Marks in Sustainability and ESG Efforts
- Paychex Board Announces Dividend for Shareholders
- FEMSA Partners with TRAXIÓN to Enhance Logistics Strategy
- Anthology Honored by Microsoft as an Inner Circle Member for 2024-2025
- PGIM Multi-Asset Solutions Expands Management Team for Growth
- JanSport Launches New Retro Series with Vintage Flair
- Velan Inc. Partners with GEH for Historic Small Modular Reactor
Recent Articles
- Zapp EV Collaborates with AIH Group for New Manufacturing Hub
- China's Ambitious $24B Investment in Coal-to-Oil Technology
- Blue Moon Metals Moves Forward with Economic Assessment of Project
- Atsena Therapeutics Showcases Innovative Gene Therapy Data
- Intellia Therapeutics Schedules Investor Webcast on NTLA-2002
- Pharmaceutical Excipient Market Set for Growth Beyond $1.58B
- Opthea's Breakthrough Presentation on Wet AMD at Innovate Retina
- Theratechnologies Achieves Remarkable Q3 Growth and Profits
- NexGold and Signal Gold Merger: A New Era for Gold Development
- Three Promising Tech Stocks Set for Recovery Soon
- Microsoft's AI Innovations: A Competitive Landscape Unveiled
- Candor Technology Innovates FHA Loan Automation with Warranty
- Mallinckrodt Launches Innovative INOmax Delivery System Nationwide
- iQSTEL and Cycurion Team Up to Transform Cybersecurity Landscape
- CULT Food Science Strengthens Leadership with New Sales Head
- Brahm Spilfogel Appointed to Nuclear Fuels' Board of Directors
- Grown Rogue Ends Advisory Deal, Focuses on Strategic Growth
- Tilray Celebrates Record $200 Million Q1 Revenue Surge
- Patagonia Gold Strengthens Mina Angela with New Acquisitions
- Argentina Faces Struggles Amid High Inflation Despite Slowdown
- InMode Anticipates Robust Q3 2024 Financial Results
- Elon Musk's X Exempt from New EU Digital Markets Regulations
- Pet Valu to Reveal Third Quarter 2024 Results and Insights
- Suki Secures $70 Million to Enhance AI Healthcare Solutions
- Neogen Corporation Reports First Quarter 2025 Financial Results
- Tilray Surprises with Q1 Earnings Growth Amid Revenue Shortfall
- Why Robinhood Stocks Are Driving Rapid Growth In 2024
- Virtus Investment Partners Sees Growth with $183.7 Billion AUM
- A2Z Cust2mate's Growth Strategy Unfolds in Latin America
- Aircastle Limited Reports Strong Q2 Results Highlighting Growth
- Plurilock and CrowdStrike Join Forces to Bolster Cybersecurity
- Indivior Adjusts Financial Outlook in Response to Market Trends
- Chuze Fitness Expands Offerings with CLMBR Vertical Machines
- Goldman Sachs Adjusts Microsoft Stock Target Amid AI Growth
- YXT.com Surpasses 200 Fortune 500 Clients Amid Challenges
- ServiceNow Set to Thrive with Upgraded Price Target and AI Growth
- CloudM Launches Migrate 4.0: A Revolution in Data Migration
- Zoom Video’s Future Growth: Insights and Strategies Unveiled
- Life Time Champions Expanding Pickleball Facilities Across U.S.
- Cabaletta Bio Gears Up for Growth with CABA-201 and Key Insights
- ToolsGroup Recognized as Leader in Global Supply Chain Solutions
- Analysts Boost Kyverna Therapeutics' Stock Rating Amid Promising Data
- IKEA Reports 5% Sales Decline Amid Housing Market Challenges
- Domino's Pizza Shows Resilience with Strong Earnings Performance
- Key Stock Movements: Tesla and GXO Rise, Delta and Apple Drop
- Microsoft Ranks High in CIOs' AI Investment Priorities
- Airbus Faces Challenges in Meeting 2023 Delivery Goals
- Top 3 Dynamic Stocks with Strong Upside Potential
- Market Movers: Key Insights on Pfizer, Arcadium Lithium, and Netflix
- Navigating Nasdaq 100 Gains Amid Risk Factors